Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases

Launched by IRCCS SAN RAFFAELE · Mar 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how effective assisted reproductive techniques (ARTs) are for women with systemic rheumatic diseases, such as lupus or arthritis, who are trying to conceive. The researchers want to understand how these treatments affect both the women’s health and the outcomes of their pregnancies. They are particularly interested in women whose diseases are stable, as well as those with specific conditions like Systemic Lupus Erythematosus (SLE) and Anti-Phospholipid Antibody Syndrome (APS), to ensure they receive the best care during their fertility treatments and pregnancies.

To participate in this trial, women aged 18 to 45 who have been diagnosed with certain systemic rheumatic diseases and have undergone at least one fertility treatment between January 2000 and April 2021 may be eligible. Participants can expect to be closely monitored throughout the study to assess both their health and the success of the fertility treatments they receive. It’s important to note that women with only one organ autoimmunity or severe health issues, such as serious kidney problems or heart disease, will not be included in this trial.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with systemic immunoreumatologic disease such as SLE, APS, RA, SpA, SclS, SS, PM-DM, vasculitis
• • patients who have performed one or more PMAs between January 2000 and April 2021
• • patients who had their last follow-up by February 2022
• Exclusion Criteria:
• • Patients diagnosed with only one organ autoimmunity (e.g., diabetes mellitus I, thyroiditis of Hashimoto's, celiac disease or chronic inflammatory bowel disease in the absence of systemic disease associated);
• • patients with severe renal failure, significant pulmonary hypertension or cardiomyopathy severe.